{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:59:49Z","timestamp":1793660389370,"version":"4.5.1"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T00:00:00Z","timestamp":1689811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Human babesiosis cases are emerging with an increased incidence and a wider geographic range worldwide. Relapsing babesiosis cases are becoming more frequently encountered in clinical practice associated with the use of immunosuppressive medications. The 2020 Infectious Diseases Society of America babesiosis guideline recommends at least 6 weeks of antimicrobial treatment for highly immunocompromised patients with Babesia microti infection. Nevertheless, cases have relapsed even after 6 weeks of treatment. Genetic mutations regarded as the potential cause of antimicrobial resistance in B microti have been identified in certain relapsing cases. A few alternative antimicrobial regimens have been used successfully to achieve cure for some of these cases, but other cases have had fatal outcomes. In this review, we discuss the molecular evidence of genetic resistance to certain antimicrobials commonly used to treat B microti infections based on an evaluation of 9 patients with relapsing infection.<\/jats:p>","DOI":"10.1093\/ofid\/ofad391","type":"journal-article","created":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T17:15:16Z","timestamp":1689873316000},"source":"Crossref","is-referenced-by-count":15,"title":["Relapsing Babesiosis With Molecular Evidence of Resistance to Certain Antimicrobials Commonly Used to Treat <i>Babesia microti<\/i> Infections"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3589-0432","authenticated-orcid":false,"given":"Luis A","family":"Marcos","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Stony Brook University , Stony Brook, New York , USA"},{"name":"Department of Microbiology and Immunology, Stony Brook University , Stony Brook, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary P","family":"Wormser","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, New York Medical College , Valhalla, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,7,20]]},"reference":[{"key":"2023083120070545700_ofad391-B1","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.idc.2015.02.008","article-title":"Babesiosis","volume":"29","author":"Vannier","year":"2015","journal-title":"Infect Dis Clin North Am"},{"key":"2023083120070545700_ofad391-B2","doi-asserted-by":"crossref","first-page":"273","DOI":"10.15585\/mmwr.mm7211a1","article-title":"Trends in reported babesiosis cases\u2014United States, 2011\u20132019","volume":"72","author":"Swanson","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2023083120070545700_ofad391-B3","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/MOH.0000000000000606","article-title":"Human babesiosis: recent advances and future challenges","volume":"27","author":"Lobo","year":"2020","journal-title":"Curr Opin Hematol"},{"key":"2023083120070545700_ofad391-B4","doi-asserted-by":"crossref","first-page":"354","DOI":"10.3201\/eid2802.210213","article-title":"Epidemiology of hospitalized patients with babesiosis, United States, 2010\u20132016","volume":"28","author":"Bloch","year":"2022","journal-title":"Emerg Infect Dis"},{"key":"2023083120070545700_ofad391-B5","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/14787210.2020.1752193","article-title":"Management strategies for human babesiosis","volume":"18","author":"Smith","year":"2020","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2023083120070545700_ofad391-B6","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/cid\/ciab050","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America (IDSA): 2020 guideline on diagnosis and management of babesiosis","volume":"72","author":"Krause","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023083120070545700_ofad391-B7","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3390\/pathogens8030102","article-title":"Persistence of Babesia microti infection in humans","volume":"8","author":"Bloch","year":"2019","journal-title":"Pathogens"},{"key":"2023083120070545700_ofad391-B8","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1086\/649859","article-title":"Emergence of resistance to azithromycin-atovaquone in immunocompromised patients with Babesia microti infection","volume":"50","author":"Wormser","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2023083120070545700_ofad391-B9","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1086\/525852","article-title":"Persistent and relapsing babesiosis in immunocompromised patients","volume":"46","author":"Krause","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2023083120070545700_ofad391-B10","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1056\/NEJM200011163432004","article-title":"Atovaquone and azithromycin for the treatment of babesiosis","volume":"343","author":"Krause","year":"2000","journal-title":"N Engl J Med"},{"key":"2023083120070545700_ofad391-B11","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1515\/biol-2022-0448","article-title":"Babesia microti-induced fulminant sepsis in an immunocompromised host: a case report and the case-specific literature review","volume":"17","author":"Conte","year":"2022","journal-title":"Open Life Sci"},{"key":"2023083120070545700_ofad391-B12","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/cid\/ciac473","article-title":"Broad antimicrobial resistance in a case of relapsing babesiosis successfully treated with tafenoquine","volume":"76","author":"Rogers","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2023083120070545700_ofad391-B13","doi-asserted-by":"crossref","DOI":"10.1016\/j.idcr.2022.e01460","article-title":"Use of tafenoquine to treat a patient with relapsing babesiosis with clinical and molecular evidence of resistance to azithromycin and atovaquone","volume":"27","author":"Marcos","year":"2022","journal-title":"IDCases"},{"key":"2023083120070545700_ofad391-B14","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.3390\/pathogens11091051","article-title":"Failure of an approximately six week course of tafenoquine to completely eradicate Babesia microti infection in an immunocompromised patient","volume":"11","author":"Prasad","year":"2022","journal-title":"Pathogens"},{"key":"2023083120070545700_ofad391-B15","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1093\/cid\/cix477","article-title":"Clinical and molecular evidence of atovaquone and azithromycin resistance in relapsed Babesia microti infection associated with rituximab and chronic lymphocytic leukemia","volume":"65","author":"Simon","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2023083120070545700_ofad391-B16","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab323","article-title":"Relapsed Babesia microti infection following allogeneic hematopoietic cell transplantation in a patient with B-cell acute lymphoblastic leukemia: case report and review of the literature","volume":"8","author":"Rosenblatt","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2023083120070545700_ofad391-B17","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.diagmicrobio.2016.02.016","article-title":"Persistence of babesiosis for &gt;2 years in a patient on rituximab for rheumatoid arthritis","volume":"85","author":"Raffalli","year":"2016","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2023083120070545700_ofad391-B18","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1086\/523731","article-title":"Treatment of refractory Babesia microti infection with atovaquone-proguanil in an HIV-infected patient: case report","volume":"45","author":"Vyas","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2023083120070545700_ofad391-B19","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1128\/AAC.44.8.2100-2108.2000","article-title":"Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site","volume":"44","author":"Korsinczky","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"2023083120070545700_ofad391-B20","doi-asserted-by":"crossref","first-page":"16079","DOI":"10.1038\/nmicrobiol.2016.79","article-title":"A global map of genetic diversity in Babesia microti reveals strong population structure and identifies variants associated with clinical relapse","volume":"1","author":"Lemieux","year":"2016","journal-title":"Nat Microbiol"},{"key":"2023083120070545700_ofad391-B21","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofad097","article-title":"Babesia microti variant with multiple resistance mutations detected in an immunocompromised patient receiving atovaquone prophylaxis","volume":"10","author":"Holbrook","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2023083120070545700_ofad391-B22","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1002\/acr.22345","article-title":"Pancytopenia and cough in a man with amyopathic dermatomyositis","volume":"66","author":"Mecchella","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2023083120070545700_ofad391-B23","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ijmm.2007.01.002","article-title":"First case of human babesiosis in Germany\u2014clinical presentation and molecular characterization of the pathogen","volume":"297","author":"H\u00e4selbarth","year":"2007","journal-title":"Int J Med Microbiol"},{"key":"2023083120070545700_ofad391-B24","doi-asserted-by":"crossref","first-page":"102731","DOI":"10.1016\/j.msard.2020.102731","article-title":"Babesia microti infection in a patient with multiple sclerosis treated with ocrelizumab","volume":"48","author":"Haberli","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"2023083120070545700_ofad391-B25","doi-asserted-by":"crossref","first-page":"103021","DOI":"10.1016\/j.msard.2021.103021","article-title":"Real-world experience of ocrelizumab initiation in a diverse multiple sclerosis population","volume":"53","author":"Coban","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"2023083120070545700_ofad391-B26","doi-asserted-by":"crossref","DOI":"10.1016\/j.idcr.2022.e01570","article-title":"Hemagophagocytic lymphohistiocytosis associated with recurrent babesiosis with Lyme disease co-infection in an immunocompromised host on anti-CD20 monoclonal antibody therapy: a case report","volume":"29","author":"Zahra","year":"2022","journal-title":"IDCases"},{"key":"2023083120070545700_ofad391-B27","first-page":"597","article-title":"Severe babesiosis with associated splenic infarcts and asplenia","volume":"34","author":"Sporn","year":"2021","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"2023083120070545700_ofad391-B28","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1182\/blood-2016-05-717900","article-title":"Unexpected babesiosis in a patient with worsening anemia after allogeneic hematopoietic stem cell transplantation","volume":"128","author":"Bade","year":"2016","journal-title":"Blood"},{"key":"2023083120070545700_ofad391-B29","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa448","article-title":"Case report: overwhelming Babesia parasitemia successfully treated promptly with RBC apheresis and triple therapy with clindamycin, azithromycin, and atovaquone","volume":"7","author":"Li","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2023083120070545700_ofad391-B30","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/(SICI)1098-1101(1998)13:1<32::AID-JCA7>3.0.CO;2-A","article-title":"Therapeutic apheresis for babesiosis","volume":"13","author":"Evenson","year":"1998","journal-title":"J Clin Apher"},{"key":"2023083120070545700_ofad391-B31","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.transci.2019.07.010","article-title":"Repeat exchange transfusion for treatment of severe babesiosis","volume":"58","author":"Radcliffe","year":"2019","journal-title":"Transfus Apher Sci"},{"key":"2023083120070545700_ofad391-B32","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1093\/infdis\/jiab537","article-title":"Combination of clofazimine and atovaquone as a potent therapeutic regimen for the radical cure of Babesia microti infection in immunocompromised hosts","volume":"225","author":"Tuvshintulga","year":"2022","journal-title":"J Infect Dis"},{"key":"2023083120070545700_ofad391-B33","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.20151519","article-title":"Radical cure of experimental babesiosis in immunodeficient mice using a combination of an endochin-like quinolone and atovaquone","volume":"213","author":"Lawres","year":"2016","journal-title":"J Exp Med"},{"issue":"3\u20134","key":"2023083120070545700_ofad391-B34","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.vetpar.2013.06.006","article-title":"The in vitro interactions and in vivo efficacy of atovaquone and proguanil against Babesia gibsoni infection in dogs","volume":"197","author":"Iguchi","year":"2013","journal-title":"Vet Parasitol"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofad391\/50918028\/ofad391.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/10\/8\/ofad391\/51050951\/ofad391.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/10\/8\/ofad391\/51050951\/ofad391.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T20:15:17Z","timestamp":1693512917000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofad391\/7227040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,20]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofad391","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,8]]},"published":{"date-parts":[[2023,7,20]]},"article-number":"ofad391"}}